← All Repligen CORP filings

Repligen CORP Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
RGEN
Repligen CORP
SCHEDULE: T. Rowe Price Updates Stake in Repligen Corp
T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of Repligen Corp. common stock as of June 30, 2026.
NASDAQ
RGEN
Repligen CORP
SCHEDULE: Vanguard Discloses 5% Stake in Repligen Corp
Vanguard Capital Management has reported beneficial ownership of 5% of Repligen Corp's common stock as of June 30, 2026.
NASDAQ
RGEN
Repligen CORP
SCHEDULE: Vanguard Group Updates Repligen Corp Ownership
The Vanguard Group filed an amended Schedule 13G for Repligen Corp, reporting zero beneficial ownership following an internal realignment.
NASDAQ
RGEN
Repligen CORP
SCHEDULE: Eddleman Trusts Reduce Repligen Stake Below 5%
The Roy T. Eddleman Living Trust and associated charitable trusts have reduced their aggregate beneficial ownership in Repligen Corporation to 4.86% of common stock.
NASDAQ
RGEN
Repligen CORP
SCHEDULE: T. Rowe Price Boosts Stake in Repligen to 6.1%
T. Rowe Price Associates, Inc. has disclosed a 6.1% beneficial ownership stake in Repligen Corp. common stock.
NASDAQ
RGEN
Repligen CORP
SCHEDULE 13G/A: BlackRock Maintains Significant Stake in Repligen Corporation, Discloses 9.3% Beneficial Ownership
BlackRock, Inc. has filed an amendment to its Schedule 13G, reaffirming its beneficial ownership of 9.3% of Repligen Corporation's common stock as of March 31, 2025.
NASDAQ
RGEN
Repligen CORP
SCHEDULE 13G/A: T. Rowe Price Associates Discloses 12.7% Stake in Repligen Corp
T. Rowe Price Associates, Inc. has reported a 12.7% beneficial ownership stake in Repligen Corp, holding over 7.1 million shares as of December 31, 2024.
NASDAQ
RGEN
Repligen CORP
SCHEDULE 13G/A: Eddleman Trusts Disclose 5.93% Passive Stake in Repligen Corporation
Three trusts associated with the late Roy T. Eddleman have collectively disclosed a 5.93% passive beneficial ownership stake in Repligen Corporation's common stock as of December 31, 2024.